InMed Pharmaceuticals 株価情報 (NASDAQ: INM)

最新ニュース InMed Pharmaceuticals (NASDAQ:INM) 株価情報

InMed Pharmaceuticals

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

InMed Pharmaceuticals Inc. - Common Shares

InMed Pharmaceuticals Inc

INmune Bio Inc

InMode Ltd

Inca Minerals Ltd

iShares Intermediate Muni Income Active ETF

Capital One Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) reported decent results <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43135162/capital-one-posts-q4-earnings-beat-analysts-weigh-in-on-discover-acquisition" target="_blank" rel="noreferrer noopener">for the fourth quarter</a>. The company reported its quarterly results amid an <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">exciting earnings season</a>. 
Goldman Sachs analyst Ryan M. Nash is optimistic about future performance of Capital One Financial despite slight post-market share decline.
They see stabilizing credit metrics, decreasing losses, and a continued downward trend in allowances as positive signs.
The DFS deal is expected to increase EPS power to over $22, with no major <a href="https://www.benzinga.com/m-a/24/02/37204534/capital-one-set-to-acquire-discover-in-landmark-35-3b-deal">efficiency risks despite compliance investments.</a>
Capital One Financial&#8217;s strong CET1 ratio positions it to return significant capital in the future.
With shares currently trading at just over 10x 2026E EPS, the analyst sees a potential upside as the market gains confidence in the company&#8217;s earnings and network scalability.
Once these factors are fully recognized, the analyst expects significant upside potential for the shares.
Also Read: <a target="_blank" href="https://www.benzinga.com/etfs/sector-etfs/25/01/43135764/trumps-500-billion-stargate-ai-plan-puts-3-etfs-in-focus" rel="noreferrer noopener">Trump&#8217;s $500 Billion Stargate AI Plan Puts 3 ETFs In Focus</a>
Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>) reported a solid fourth quarter PPNR beat as stronger than expected fees drove the beat while expenses and NII were in-line.
Per Nash, the beat on fees was driven by strength in commercial banking and capital markets (under new disclosures), as the three-pronged fee strategy (wealth, payments, and capital markets) continues to deliver strong results.
The analyst is optimistic about Fifth Third&#8217;s fundamentals, citing record net interest income in 2025, improved loan growth, and margin expansion. Fee income growth is also a strength, and with a CET1 ratio of 10.5%, FITB is well-positioned for capital returns.
Nash notes that shares are trading at a slight premium to peers, but the analyst sees the company to maintain or even widen that premium if it continues executing well and driving positive operating leverage while investing for growth.
See Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43128141/tech-stocks-rise-after-trump-announces-ai-infrastructure-investment" target="_blank" rel="noreferrer noopener">Tech Stocks Rise After Trump Announces AI Infrastructure Investment</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Equities

News

Markets

Analyst Ratings

Movers

Trading Ideas

General

FITB

Capital One And Fifth Third Bancorp's Capital Strength And Growth Prospects; Analyst Sees Upside

On Wednesday, IMMvention Therapeutix, Inc. announced a strategic collaboration and license agreement with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) to co-develop oral therapies for sickle cell disease (SCD) and other chronic conditions.
The <a target="_blank" href="https://www.globenewswire.com/news-release/2025/01/22/3013435/0/en/IMMvention-Therapeutix-Enters-Strategic-Collaboration-with-Novo-Nordisk-to-Develop-Oral-Therapies-for-Sickle-Cell-Disease-and-Other-Chronic-Diseases.html" rel="noreferrer noopener">partnership</a> will leverage IMMvention's investigational small-molecule BACH1 inhibitors.
BACH1 is thought to be a key regulator of cellular responses, oxidative stress and inflammation in multiple disease states.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43062779/popular-ozempic-wegovy-selected-for-next-round-of-medicare-drug-price-negotiations" rel="noreferrer noopener">Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations</a>
In preclinical development, IMMvention's orally dosed BACH1 inhibitors can potentially increase fetal hemoglobin, which is believed to ameliorate SCD disease pathology.
Under the agreement, Novo Nordisk will gain an exclusive worldwide license to IMMvention's BACH1 program. The companies will work together closely to advance BACH1 inhibitors from the program to development candidate nomination.
Upon or before the nomination of a development candidate, Novo Nordisk will take over all further development, regulatory submissions and commercialization worldwide.
Separate from the systemic BACH1 inhibitors that are part of the collaboration, IMMvention has retained the rights to develop certain brain-penetrant BACH1 inhibitors.
Brain penetrant BACH1 inhibitors have the potential to address diseases such as Parkinson's, Alzheimer's, and other diseases where dysregulation of BACH1 is thought to contribute to disease pathology.
IMMvention's website&nbsp;<a target="_blank" href="https://www.immventionthera.com/approach-and-pipeline" rel="noreferrer noopener">lists</a> the anticipated milestones, with Investigational New Drug-IND enabling studies and Phase 1 clinical trials in 2026/27.
Price Action: NVO stock is down 0.27% at $80.82 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43127009/textron-reports-mixed-q4-faces-challenges-in-aviation-and-industrial-segments" target="_blank" rel="noreferrer noopener">Textron Reports Mixed Q4, Faces Challenges In Aviation And Industrial Segments</a></li>
</ul>

Biotech

Large Cap

Health Care

Contracts

Novo Nordisk Inks License Agreement For Sickle Cell Disease Candidate

Ratings for Pinnacle Finl Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNFP#NASDAQ">PNFP</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Pinnacle Finl Partners, revealing an average target of $132.22, a high estimate of $142.00, and a low estimate of $120.00. This upward trend is evident, with the current average reflecting a 11.47% increase from the previous average price target of $118.62.
<img src="https://www.benzinga.com/files/images/story/2025/1737576059_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Pinnacle Finl Partners. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Russell Gunther</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$142.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Anthony Elian</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$138.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Ben Gerlinger</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$132.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Vilas Abraham</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$133.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Catherine Mealor</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$135.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Steven Shaw</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Brett Rabatin</td>
<td>Hovde Group</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$135.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pinnacle Finl Partners. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pinnacle Finl Partners compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Pinnacle Finl Partners's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Pinnacle Finl Partners's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PNFP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pinnacle Finl Partners analyst ratings.</a>
<h2>Unveiling the Story Behind Pinnacle Finl Partners</h2>
Pinnacle Financial Partners Inc is a financial holding company. The company operates through its wholly-owned subsidiary, Pinnacle Bank. The bank provides a full range of lending products, including commercial, real estate, and consumer loans to individuals and small to medium-sized businesses. Pinnacle operates as a community bank mainly in the urban markets of Nashville, Knoxville, Memphis, and Chattanooga, Tennessee, as well as surrounding counties. It relies heavily on mergers and acquisitions. A majority of its loan portfolio is in commercial loans, mainly real estate, as well as industrial loans. The bank generates a majority of its net revenue through net interest income.
<h3>Pinnacle Finl Partners: A Financial Overview</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Pinnacle Finl Partners's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 16.61%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 35.03%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Pinnacle Finl Partners's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.36%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Pinnacle Finl Partners's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.29%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.42, Pinnacle Finl Partners adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PNFP

The Analyst Verdict: Pinnacle Finl Partners In The Eyes Of 9 Experts

In the preceding three months, 9 analysts have released ratings for ACV Auctions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NASDAQ">ACVA</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated ACV Auctions and provided 12-month price targets. The average target is $24.5, accompanied by a high estimate of $28.00 and a low estimate of $18.00. This current average has increased by 5.97% from the previous average price target of $23.12. 
<img src="https://www.benzinga.com/files/images/story/2025/1737576052_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive ACV Auctions is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Imbro</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$20.50</td>
<td>-</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$27.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Naved Khan</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$27.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Alexander Potter</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$23.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ACV Auctions. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of ACV Auctions compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of ACV Auctions's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ACVA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ACV Auctions analyst ratings.</a>
<h2>About ACV Auctions</h2>
ACV Auctions Inc is a mobile platform for wholesale car auctions. It provides a digital marketplace for wholesale vehicle transactions and data services that offer transparent and accurate vehicle information for customers.
<h3>Unraveling the Financial Story of ACV Auctions</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: ACV Auctions displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 43.96%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: ACV Auctions's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -9.36%, the company may face hurdles in effective cost management.
Return on Equity (ROE): ACV Auctions's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -3.51%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): ACV Auctions's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.57%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.25, ACV Auctions adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACVA

9 Analysts Have This To Say About ACV Auctions

In the latest quarter, 31 analysts provided ratings for Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">12</td>
<td align="right">15</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">9</td>
<td align="right">12</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $123.71, along with a high estimate of $150.00 and a low estimate of $95.00. Marking an increase of 17.67%, the current average surpasses the previous average price target of $105.13. 
<img src="https://www.benzinga.com/files/images/story/2025/1737576043_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Marvell Tech's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Vinh</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Aaron Rakers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Toshiya Hari</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$131.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Christian Schwab</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$149.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Tore Svanberg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Toshiya Hari</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Harlan Sur</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Gary Mobley</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Hold</td>
<td>$110.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>John Vinh</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Christian Schwab</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$132.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Rick Schafer</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Tore Svanberg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$102.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$127.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Hans Mosesmann</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$122.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$110.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Rick Schafer</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Aaron Rakers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Gary Mobley</td>
<td>Loop Capital</td>
<td>Announces</td>
<td>Hold</td>
<td>$95.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Marvell Tech. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Marvell Tech compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Marvell Tech's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Marvell Tech's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MRVL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Marvell Tech analyst ratings.</a>
<h2>Get to Know Marvell Tech Better</h2>
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.
<h3>Understanding the Numbers: Marvell Tech's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Marvell Tech's revenue growth over a period of 3 months has been noteworthy. As of 31 October, 2024, the company achieved a revenue growth rate of approximately 6.87%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Marvell Tech's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -44.61%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Marvell Tech's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -4.9%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Marvell Tech's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -3.38%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Marvell Tech's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.32.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MRVL

The Analyst Verdict: Marvell Tech In The Eyes Of 31 Experts

Ratings for Camden Prop Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPT#NYSE">CPT</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $127.14, with a high estimate of $138.00 and a low estimate of $121.00. This current average has increased by 0.11% from the previous average price target of $127.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1737576035_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Camden Prop Trust. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$121.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Vikram Malhorta</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Anthony Powell</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$138.00</td>
<td>-</td>
</tr>
<tr>
<td>Anthony Paolone</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$128.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$130.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Simon Yarmak</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$121.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$127.00</td>
<td>$131.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Camden Prop Trust. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Camden Prop Trust compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Camden Prop Trust's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Camden Prop Trust's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CPT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Camden Prop Trust analyst ratings.</a>
<h2>About Camden Prop Trust</h2>
Camden Property Trust is a real estate investment trust primarily engaged in the acquisition, management, and development of multifamily apartment communities across the United States. The company's real estate portfolio consists primarily of apartment properties throughout the Sun Belt. Houston, Dallas, Las Vegas, and Atlanta represent some of Camden's largest housing markets in terms of apartment units. The firm derives nearly all of its revenue from the leasing of properties to tenants through short-term agreements. Camden Property derives the majority of its revenue from the Washington D.C., Los Angeles, Houston, Atlanta, and southeastern Florida areas.
<h3>A Deep Dive into Camden Prop Trust's Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Challenges: Camden Prop Trust's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -0.91%. This indicates a decrease in top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Camden Prop Trust's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -1.08%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Camden Prop Trust's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.09%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Camden Prop Trust's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.05%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Camden Prop Trust's debt-to-equity ratio is below the industry average. With a ratio of 0.73, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Camden Prop Trust Through 7 Analysts

Investors with a lot of money to spend have taken a bullish stance on Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ANET, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 66 uncommon options trades for Arista Networks.
This isn't normal.
The overall sentiment of these big-money traders is split between 54% bullish and 25%, bearish.
Out of all of the special options we uncovered, 14 are puts, for a total amount of $812,079, and 52 are calls, for a total amount of $3,454,782.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $50.0 to $170.0 for Arista Networks during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Arista Networks's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Arista Networks's substantial trades, within a strike price spectrum from $50.0 to $170.0 over the preceding 30 days.
<h3>Arista Networks Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737576036_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$37.6</td>
<td>$37.1</td>
<td>$37.32</td>
<td>$97.50</td>
<td>$149.2K</td>
<td>777</td>
<td align="right">43</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$18.8</td>
<td>$18.2</td>
<td>$18.4</td>
<td>$125.00</td>
<td>$147.2K</td>
<td>1.8K</td>
<td align="right">115</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$36.5</td>
<td>$35.8</td>
<td>$35.6</td>
<td>$95.00</td>
<td>$142.5K</td>
<td>980</td>
<td align="right">52</td>
</tr>
<tr>
<td>ANET</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.8</td>
<td>$3.6</td>
<td>$3.6</td>
<td>$120.00</td>
<td>$140.4K</td>
<td>819</td>
<td align="right">432</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$16.2</td>
<td>$16.0</td>
<td>$16.0</td>
<td>$120.00</td>
<td>$139.2K</td>
<td>2.5K</td>
<td align="right">343</td>
</tr>
</tbody>
</table>

<h3>About Arista Networks</h3>
Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.
In light of the recent options history for Arista Networks, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Arista Networks's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 6,317,790, the ANET's price is up by 3.56%, now at $125.83. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 27 days.</li>
</ul>
<h3>What Analysts Are Saying About Arista Networks</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $132.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on Arista Networks with a target price of $130. 
&#x2A; An analyst from Goldman Sachs has decided to maintain their Buy rating on Arista Networks, which currently sits at a price target of $135. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Arista Networks with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

ANET

Spotlight on Arista Networks: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bullish stance on Alibaba Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BABA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 65 uncommon options trades for Alibaba Gr Hldgs.
This isn't normal.
The overall sentiment of these big-money traders is split between 47% bullish and 40%, bearish.
Out of all of the special options we uncovered, 12 are puts, for a total amount of $1,021,910, and 53 are calls, for a total amount of $4,965,428.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $40.0 and $140.0 for Alibaba Gr Hldgs, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Alibaba Gr Hldgs's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Alibaba Gr Hldgs's substantial trades, within a strike price spectrum from $40.0 to $140.0 over the preceding 30 days.
<h3>Alibaba Gr Hldgs 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737576031_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BABA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$1.81</td>
<td>$1.81</td>
<td>$1.81</td>
<td>$82.00</td>
<td>$255.8K</td>
<td>6</td>
<td>1.4K</td>
</tr>
<tr>
<td>BABA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$6.55</td>
<td>$6.15</td>
<td>$6.3</td>
<td>$140.00</td>
<td>$252.0K</td>
<td>2.1K</td>
<td>400</td>
</tr>
<tr>
<td>BABA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$12.15</td>
<td>$11.9</td>
<td>$12.15</td>
<td>$80.00</td>
<td>$243.0K</td>
<td>3.8K</td>
<td>211</td>
</tr>
<tr>
<td>BABA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$15.7</td>
<td>$15.55</td>
<td>$15.7</td>
<td>$100.00</td>
<td>$188.4K</td>
<td>3.5K</td>
<td>571</td>
</tr>
<tr>
<td>BABA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$9.2</td>
<td>$9.0</td>
<td>$9.08</td>
<td>$100.00</td>
<td>$182.3K</td>
<td>13.8K</td>
<td>516</td>
</tr>
</tbody>
</table>

<h3>About Alibaba Gr Hldgs</h3>
Alibaba is the world's largest online and mobile commerce company as measured by gross merchandise volume. It operates China's online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). The China commerce retail division is the most valuable cash flow-generating business at Alibaba. Additional revenue sources include China commerce wholesale, international commerce retail/wholesale, local consumer services, cloud computing, digital media and entertainment platforms, Cainiao logistics services, and innovation initiatives/other.
Having examined the options trading patterns of Alibaba Gr Hldgs, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Alibaba Gr Hldgs Standing Right Now?</h3>
<ul>
<li>With a trading volume of 7,324,418, the price of BABA is up by 1.02%, reaching $86.25.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 14 days from now.</li>
</ul>
<h3>What The Experts Say On Alibaba Gr Hldgs</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $138.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Alibaba Gr Hldgs, targeting a price of $138. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Alibaba Gr Hldgs with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

BABA

Alibaba Gr Hldgs Unusual Options Activity

Whales with a lot of money to spend have taken a noticeably bearish stance on KLA.
Looking at options history for KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) we detected 17 trades.
If we consider the specifics of each trade, it is accurate to state that 41% of the investors opened trades with bullish expectations and 47% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $444,070 and 11, calls, for a total amount of $873,824.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $680.0 and $920.0 for KLA, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for KLA's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across KLA's significant trades, within a strike price range of $680.0 to $920.0, over the past month.
<h3>KLA Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737576026_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$74.2</td>
<td>$72.5</td>
<td>$72.5</td>
<td>$840.00</td>
<td>$174.0K</td>
<td align="right">1</td>
<td align="right">31</td>
</tr>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$84.1</td>
<td>$79.7</td>
<td>$84.1</td>
<td>$880.00</td>
<td>$168.2K</td>
<td align="right">24</td>
<td align="right">20</td>
</tr>
<tr>
<td>KLAC</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$29.5</td>
<td>$27.6</td>
<td>$28.55</td>
<td>$750.00</td>
<td>$142.7K</td>
<td align="right">10</td>
<td align="right">50</td>
</tr>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$60.4</td>
<td>$57.5</td>
<td>$57.61</td>
<td>$820.00</td>
<td>$115.3K</td>
<td align="right">131</td>
<td align="right">21</td>
</tr>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$56.9</td>
<td>$53.1</td>
<td>$55.8</td>
<td>$760.00</td>
<td>$111.3K</td>
<td align="right">65</td>
<td align="right">20</td>
</tr>
</tbody>
</table>

<h3>About KLA</h3>
KLA is one of the largest semiconductor wafer fabrication equipment, or WFE, manufacturers in the world. It specializes in the market segment of semiconductor process control, wherein machines inspect semiconductor wafers during research and development and manufacturing for defects and verify precise measurements. In this section of the market, KLA holds a majority share. It also has a small exposure to the etch and deposition segments of the WFE market. It counts as top customers the largest chipmakers in the world, including TSMC and Samsung.
Having examined the options trading patterns of KLA, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>KLA's Current Market Status</h3>
<ul>
<li>Trading volume stands at 396,051, with KLAC's price up by 0.98%, positioned at $774.77.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 8 days.</li>
</ul>
<h3>Professional Analyst Ratings for KLA</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $737.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on KLA with a target price of $795. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for KLA, targeting a price of $700. 
&#x2A; An analyst from Susquehanna persists with their Neutral rating on KLA, maintaining a target price of $655. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on KLA with a target price of $759. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on KLA with a target price of $780. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest KLA options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

KLAC

Check Out What Whales Are Doing With KLAC

In the preceding three months, 6 analysts have released ratings for Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $10.67, a high estimate of $13.00, and a low estimate of $9.00. A 11.08% drop is evident in the current average compared to the previous average price target of $12.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1737576025_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Ford Motor among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Philippe Houchois</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$9.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Daniel Roeska</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$11.00</td>
<td>-</td>
</tr>
<tr>
<td>Edison Yu</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Tom Narayan</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ford Motor. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ford Motor compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Ford Motor's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Ford Motor's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/F/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ford Motor analyst ratings.</a>
<h2>Unveiling the Story Behind Ford Motor</h2>
Ford Motor Co. manufactures automobiles under its Ford and Lincoln brands. In March 2022, the company announced that it will run its combustion engine business, Ford Blue, and its BEV business, Ford Model e, as separate businesses but still all under Ford Motor. The company has nearly 13% market share in the United States, about 11% share in the UK, and under 2% share in China including unconsolidated affiliates. Sales in the US made up about 66% of 2023 total company revenue. Ford has about 177,000 employees, including about 59,000 UAW employees, and is based in Dearborn, Michigan.
<h3>Key Indicators: Ford Motor's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Ford Motor showcased positive performance, achieving a revenue growth rate of 5.47% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Ford Motor's net margin excels beyond industry benchmarks, reaching 1.93%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Ford Motor's ROE stands out, surpassing industry averages. With an impressive ROE of 2.03%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.32%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 3.59, Ford Motor faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Ford Motor In The Eyes Of 6 Experts

Nordson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDSN#NASDAQ">NDSN</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $263.0, a high estimate of $285.00, and a low estimate of $237.00. Observing a downward trend, the current average is 6.52% lower than the prior average price target of $281.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1737576018_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Nordson. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Dankert</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$280.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Walt Liptak</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Buy</td>
<td>$250.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Summerville</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$285.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$237.00</td>
<td>$294.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nordson. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Nordson compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Nordson's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Nordson's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NDSN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Nordson analyst ratings.</a>
<h2>Delving into Nordson's Background</h2>
Nordson manufactures equipment (including pumps, valves, dispensers, applicators, filters, and pelletizers) used for dispensing adhesives, coatings, sealants, and other materials. The firm serves a diverse range of end markets including packaging, medical, electronics, and industrial. Nordson's business is organized into three segments: industrial precision solutions, medical and fluid solutions, and advanced technology solutions. The company generated approximately $2.7 billion in revenue in its fiscal 2024.
<h3>Nordson: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Nordson showcased positive performance, achieving a revenue growth rate of 3.5% as of 31 October, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Nordson's net margin excels beyond industry benchmarks, reaching 16.41%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 4.22%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 2.18%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Nordson's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.79, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NDSN

Assessing Nordson: Insights From 4 Financial Analysts

Linde (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>) has outperformed the market over the past 10 years by 2.12% on an annualized basis producing an average annual return of 13.72%. Currently, Linde has a market capitalization of $212.74 billion. 
Buying $100 In LIN: If an investor had bought $100 of LIN stock 10 years ago, it would be worth $357.80 today based on a price of $445.53 for LIN at the time of writing.
<h3>Linde's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737576014_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Linde Stock In The Last 10 Years

Blackboxstocks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBX#NASDAQ">BLBX</a>) shares are moving higher on Wednesday after the company announced it secured financing as it anticipates <a href="https://www.benzinga.com/pressreleases/25/01/g43125093/blackboxstocks-inc-secures-financing-of-up-to-2-000-000-in-anticipation-of-potential-merger">a potential merger</a>.
What To Know: Blackboxstocks entered into a securities purchase agreement under which the purchaser agreed to buy $250,000 worth of senior debentures, as well as amended and restated senior secured convertible debentures with an aggregate principal amount of $2 million, upon certain closing conditions.
Blackboxstocks entered into the agreement on Jan. 17 and is set to receive an initial $250,000. The additional financing is tied to a potential merger deal.
&#8220;We are excited to have completed this transaction as we work towards securing a merger transaction that will create significant stockholder value. This financing will help provide the interim capital we need for our operations as well as anticipated transaction expenses in the near future,&#8221; said Gust Kepler, CEO of Blackboxstocks.
Blackboxstocks shares are moving on above-average volume of more than 197 million shares on Wednesday. The company&#8217;s average session volume over the past 100 days is around 70,000, per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Blackboxstocks is considered a low-float stock with just 2.58 million shares available for public trading, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The company also had a market cap of less than $6 million as of Wednesday's close. Low-float, micro-cap stocks can be extremely volatile, which may help explain some of Wednesday's surge.
See Also: <a href="https://www.benzinga.com/25/01/43138517/chipmakers-rally-on-ai-stargate-bet-netflix-soar-bitcoin-falters-amid-trumps-crypto-silence-whats-driving-markets-wednesday">Chipmakers Rally On AI Stargate Bet, Netflix Soars, Bitcoin Falters As Trump Keeps Quiet On Crypto: What&#8217;s Driving Markets Wednesday?</a>
BLBX Price Action: At the time of publication, Blackboxstocks shares were up 237% at $5.66, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: 5846648 from Pixabay.

BLBX

What's Going On With Blackboxstocks Shares Wednesday?

WIIM

Halliburton shares are trading lower following mixed Q4 results and guided for a North America revenue decline.

California Democrat and political commentator Van Jones characterized the act of some people buying Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) as a form of &#8220;prayer,&#8221; reflecting a hope for a better financial outcome amid economic uncertainty and frustration with governmental financial policies.
&#8220;A lot of people are buying crypto as a prayer, as a prayer for a better tomorrow, as a hope that somehow something will go good for them,&#8221; he said on Sunday.
Jones argued that the regulatory approach by the Biden administration has inadvertently <a href="https://www.benzinga.com/news/legal/24/11/41996491/18-republican-states-sue-bidens-sec-over-harsh-crypto-crackdown">stifled innovation</a> in the crypto space.
He criticized the government&#8217;s crackdown on more useful cryptocurrencies, saying, &#8220;the more useful the coin is, the more they got attacked. 
The more useless the coin is, the less they got attacked.&#8221; 
This, according to Jones, led to the current market being dominated by meme coins, due to the lack of development and innovation stifled by regulation. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43136512/bitcoin-is-no-threat-to-the-us-dollar-goldman-sachs-ceo-says">Bitcoin Is No &#8216;Threat&#8217; To The US Dollar, Goldman Sachs CEO Says</a>
He noted that instead of protecting individuals, this overregulation has led to a negative market dynamic.
Adding to the commentary, Ashley Etienne, former Communications Director for former Vice President Kamala Harris, weighed in, labeling President Donald Trump a &#8220;grifter.&#8221;
She referenced reports alleging Trump&#8217;s family made millions from foreign governments during his presidency, and warned against Trump&#8217;s potential to profit from the crypto industry and how that's an "issue of conflicts". 
Etienne emphasized that, &#8220;there was a reason why he was called the grifter in chief in his first term." 
She went on to add &#8220;the consensus was that Donald Trump can be bought, that he can be bought in influence simply by dangling some money over his head.&#8221; 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43133561/bitcoin-could-drop-up-to-20-as-trump-hope-fades-standard-chartered-warns">Bitcoin Could Drop Up To 20% As Trump &#8216;Hope&#8217; Fades, Standard Chartered Warns</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

People Buy Bitcoin As 'Prayer For A Better Tomorrow, CNN Pundit Van Jones Says As Former Harris Aide Slams Trump As 'Grifter In Chief'

CME Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CME#NYSE">CME</a>) short percent of float has fallen 9.09% since its last report. The company recently reported that it has 4.32 million shares sold short, which is 1.2% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.5 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>CME Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737575121_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for CME Gr has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing CME Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, CME Gr's peer group average for short interest as a percentage of float is 3.08%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(CME) - Analyzing CME Gr's Short Interest

GlucoTrack's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NYSE">GCTK</a>) short percent of float has risen 42.38% since its last report. The company recently reported that it has 560 thousand shares sold short, which is 4.67% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>GlucoTrack Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737575116_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for GlucoTrack has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing GlucoTrack's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, GlucoTrack's peer group average for short interest as a percentage of float is 6.31%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

GCTK

How Is The Market Feeling About GlucoTrack?

Cerence's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NYSE">CRNC</a>) short percent of float has fallen 30.7% since its last report. The company recently reported that it has 7.09 million shares sold short, which is 16.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.73 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cerence Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737575111_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cerence has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cerence's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cerence's peer group average for short interest as a percentage of float is 6.95%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CRNC

Looking Into Cerence's Recent Short Interest

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 250 points on Wednesday.
The Dow traded up 0.27% to 44,146.86 while the NASDAQ rose 1.29% to 20,010.85. The S&amp;P 500 also rose, gaining, 0.70% to 6,091.74.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/43123084/top-3-health-care-stocks-that-could-blast-off-this-quarter">Top 3 Health Care Stocks That Could Blast Off This Quarter</a>
Leading and Lagging Sectors Information technology shares surged by 2.5% on Wednesday.
In trading on Wednesday, utilities shares fell by 1.5%.
Top Headline
Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion.
Adjusted diluted earnings per share were $1.34, in line with the analyst estimates and management consensus of $1.31-$1.37, up from $1.19 a year ago.
Abbott projects full-year 2025 adjusted EPS of $5.05-$5.25 versus a consensus of $5.16, with organic sales growth of 7.5%- 8.5% and an adjusted operating margin of 23.5%- 24.0%. Abbott Laboratories expects first quarter 2025 adjusted EPS of $1.05-$1.09 versus consensus of $1.11.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Blackboxstocks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBX#NASDAQ">BLBX</a>) shares shot up 101% to $3.39 after the company announced a $250K securities purchase agreement and is anticipating a potential merger.</li>
<li>Shares of Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>)got a boost, surging 26% to $4.0450 after Needham initiated coverage with a Buy rating and a $9 price target.</li>
<li>ImmunoPrecise Antibodies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPA#NASDAQ">IPA</a>) shares were also up, gaining 30% to $0.6396 after the company announced it developed a new class of GLP-1 therapies using its LENS platform.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Agilysys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) shares dropped 21% to $100.00 after the company reported worse-than-expected third-quarter sales results and issued FY25 revenue guidance below estimates.</li>
<li>Shares of Hepion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) were down 61% to $0.1265 after the company announced a $9 million public offering.</li>
<li>Lisata Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTA#NASDAQ">LSTA</a>) was down, falling 30% to $2.72 after the company announced preliminary cohort data from its Phase 2 Ascend trial.</li>
</ul>
Commodities In commodity news, oil traded down 0.4% to $75.55 while gold traded up 0.4% at $2,770.40.
Silver traded down 0.5% to $31.33 on Wednesday, while copper fell 1% to $4.2985.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 surged 0.39%, Germany's DAX 40 rose 1.01% and France's CAC 40 gained 0.86%. Spain's IBEX 35 Index fell 0.37%, while London's FTSE 100 fell 0.04%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 gaining 1.58%, China's Shanghai Composite Index falling 0.89%, Hong Kong's Hang Seng Index falling 1.63% and India's BSE Sensex gaining 0.75%.
Economics
U.S. mortgage applications rose 0.1% from the previous week in the week ending Jan. 17.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/43125507/apple-to-183-here-are-10-top-analyst-forecasts-for-wednesday">Apple To $183? Here Are 10 Top Analyst Forecasts For Wednesday</a></li>
</ul>

Earnings

Eurozone

Commodities

Intraday Update

ABSI

AGYS

HEPA

LSTA

Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales

Goldman Sachs analyst Lizzie Dove initiated coverage on Viking Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) with a Neutral rating<a href="https://www.benzinga.com/quote/VIK/analyst-ratings" target="_blank" rel="noreferrer noopener"> and price forecast of $49.</a>
The analyst highlights that Viking Holdings&#8217; business model has strong appeal due to its high exposure to a growing demographic booking ahead at higher prices and its industry-leading category expansion, which boosts revenue growth.
However, due to the stock rising 73% since its IPO in May 2024 and a valuation premium compared to Royal Caribbean Cruises Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>), the analyst is looking for a better entry point.
The analyst also notes that Viking Holdings high booking visibility (70% booked for 2025) and its desire to maintain a cash cushion suggest less potential for near-term estimate revisions and share repurchases.
Also Read: <a target="_blank" href="https://www.benzinga.com/etfs/sector-etfs/25/01/43135764/trumps-500-billion-stargate-ai-plan-puts-3-etfs-in-focus" rel="noreferrer noopener">Trump&#8217;s $500 Billion Stargate AI Plan Puts 3 ETFs In Focus</a>
Dove points out that Viking Holdings&#8217; core demographic mainly consists of affluent US travelers aged 55+, a fast-growing group with the highest wealth, representing about 30% of the population <a href="https://www.benzinga.com//node/43065113">but over 70% of the wealth.</a>
However, the analyst notes that the company&#8217;s customer base is less new-to-cruise compared to its peers, which has been a major growth driver for the cruise industry over the past two years.
The analyst highlights that Royal Caribbean and Carnival Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) have experienced double-digit growth in new-to-cruise passengers, with around half of their guests being millennials or younger.
While Viking Holdings has an appealing demographic and a strong pipeline of potential cruisers, Dove sees less opportunity for Viking Holdings to benefit from the new-to-cruise growth that has supported the broader industry.
Price Action: VIK shares are trading lower by 1.30% to $47.86 at last check Wednesday.
See Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43128141/tech-stocks-rise-after-trump-announces-ai-infrastructure-investment" target="_blank" rel="noreferrer noopener">Tech Stocks Rise After Trump Announces AI Infrastructure Investment</a></li>
</ul>
Photo via Shutterstock.

Price Target

Initiation

Viking Holdings' Premium Valuation Warrants A More Favorable Entry Point: Analyst

Inmed Pharmaceuticals Inc. ( ($INM) ) has released its Q1 earnings. Here is a breakdown of the information Inmed Pharmaceuticals Inc. presented to ...

InMed Pharmaceuticals Reports Improved Quarterly Earnings

InMed Pharmaceuticals (INM) has released an update. InMed Pharmaceuticals has published a promising study showcasing the anti-inflammatory effects ...

InMed's Study Highlights Cannabinol's Potential in Skincare

InMed Pharmaceuticals ( ($INM) ) has issued an update. InMed Pharmaceuticals has published a study revealing the potential of cannabinol (CBN) as a...

InMed Pharmaceuticals Explores CBN for Skin Disease Treatment

InMed Pharmaceuticals (INM) has released an update. InMed Pharmaceuticals has entered into a Standby Equity Purchase Agreement with Yorkville Advis...

InMed Pharmaceuticals Secures $10 Million Equity Purchase Agreement

InMed Pharmaceuticals (INM) has released an update. InMed Pharmaceuticals announced the results of their 2024 Annual General Meeting, where shareho...

InMed Pharmaceuticals' 2024 AGM Results Announced

17:21 EST InMed Pharmaceuticals (INM) files to sell 3M common shares for holders Published first on TheFly – the ultimate source for real-time, mar...

InMed Pharmaceuticals files to sell 3M common shares for holders

InMed Pharmaceuticals ( ($INM) ) has provided an update. InMed Pharmaceuticals announced positive results from a long-term preclinical study of its...

InMed's INM-901 Shows Promising Results in Preclinical Alzheimer's Study

InMed Pharmaceuticals (INM) announces "positive" results from a long-term in vivo preclinical Alzheimer's Disease study. In the study, INM-901 demo...

InMed announces 'positive' results from in vivo preclinical Alzheimer's study

InMed Pharmaceuticals (INM) announces it has been granted an international Patent Cooperation Treaty, PCT, patent in the first of several jurisdict...

InMed Pharmaceuticals granted an international PCT patent

An update from InMed Pharmaceuticals ( ($INM) ) is now available. InMed Pharmaceuticals has announced the granting of an international Patent Coope...

InMed Pharmaceuticals Secures Key Patent for Cannabinoid Analogs

Screenshot 2024-08-27 at 5.44.40 PM

InMed Demonstrates Encouraging Data For Its Cannabinoid INM-089 In Treating Dry AMD, An Ocular Disease With Rising Patient Numbers As National Population Ages

Comments

InMed Pharmaceuticals

ニュース

最新ニュース InMed Pharmaceuticals (NASDAQ:INM) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル